GILD

Latest SEC Filings & News for GILD

4 most recent filings and news items mentioning GILD. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day
curl "https://api.brieftape.com/v1/tickers/GILD/news?limit=20"

Pull GILD filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day
BiotechJun 9, 2026Neutral

Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial

Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial

View filing at SEC.gov →
BiotechJun 8, 2026Neutral

Merck And Gilead Discontinue Phase 3 KEYNOTE-D46/EVOKE-03 Trial After Trodelvy–KEYTRUDA Combination Fails To Achieve Statistically Significant Progression-Free Survival Benefit In First-Line Metastatic NSCLC

Merck And Gilead Discontinue Phase 3 KEYNOTE-D46/EVOKE-03 Trial After Trodelvy–KEYTRUDA Combination Fails To Achieve Statistically Significant Progression-Free Survival Benefit In First-Line Metastatic NSCLC

View filing at SEC.gov →
BiotechJun 8, 2026Neutral

Gilead And Merck Report Phase 3 Results For Once-Weekly Oral HIV Regimen Islatravir/Lenacapavir; Meets Week 48 Endpoints In ISLEND-1 And ISLEND-2 Trials

Gilead And Merck Report Phase 3 Results For Once-Weekly Oral HIV Regimen Islatravir/Lenacapavir; Meets Week 48 Endpoints In ISLEND-1 And ISLEND-2 Trials

View filing at SEC.gov →
OfferingMay 20, 2026Neutral

Gilead Sciences issues $3 billion in senior notes across four tranches

Gilead Sciences filed an underwriting agreement to issue $3 billion in senior notes with maturities ranging from 2028 to 2034 at rates between 4.250% and 4.900%. The debt offering provides capital financing and reflects investor demand for the biopharmaceutical company's credit.

View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.